The Vitek-2 yeast susceptibility system (bioMérieux, Marcy l\'Étoile, France) is a fully automated commercial method that allows determination of the minimal inhibitory concentration (MIC) of 4 antifungal agents, i.e., amphotericin B, fluconazole, voriconazole, and flucytosine \[[@B1], [@B2]\]. This system has demonstrated a high level of reproducibility and has an excellent categorical agreement with the CLSI microdilution reference method \[[@B1]-[@B3]\]. Moreover, a recent study showed that the Vitek-2 system is superior to the CLSI or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution method for detecting amphotericin B-resistant *Candida* isolates \[[@B4]\]. Because of its advantages, including a significant reduction in technologist hands-on time and turnaround time \[[@B1], [@B2]\], this system has become one of the most widely used antifungal susceptibility testing systems in Korean clinical laboratories. However, nationwide data for the *in vitro* antifungal susceptibility of *Candida* bloodstream infection (BSI) isolates as determined by the Vitek-2 system are still lacking in Korea. In this study, we investigated the *in vitro* activity of 4 antifungal agents using the Vitek-2 system against *Candida* BSI isolates recovered from 15 tertiary hospitals in Korea.

During the study period (September 2007 to August 2008), 636 *Candida* BSI isolates were collected from 636 patients among the 15 tertiary hospitals in Korea. Antifungal susceptibility testing with the Vitek-2 system was performed according to the manufacturer\'s instructions \[[@B1], [@B2]\]. The categorical result was obtained according to the breakpoints provided by the Vitek-2 system for amphotericin B (susceptible \[S\], ≤1 µg/mL; intermediate, 2 µg/mL; resistant \[R\], ≥4 µg/mL), fluconazole (S, ≤8 µg/mL; susceptible dose dependence \[SDD\], 16 to 32 µg/mL; R, ≥64 µg/mL), and voriconazole (S, ≤1 µg/mL; SDD, 2 µg/mL; R, ≥4 µg/mL), and flucytosine (S, ≤4 µg/mL; intermediate, 8-16 µg/mL; R, ≥32 µg/mL).

[Table 1](#T1){ref-type="table"} summarizes the *in vitro* antifungal susceptibilities of the 636 *Candida* BSI isolates to 4 antifungal agents as determined by using the Vitek-2 system. For all 636 *Candida* BSI isolates combined, the activity of each agent (µg/mL), expressed as the MIC~50~/MIC~90~ (and the percentage of susceptible isolates) was as follows: amphotericin, 0.5/0.5 (98.1%); fluconazole, ≤1/2 (95.9%); voriconazole, ≤0.12/≤0.12 (99.1%); and flucytosine, ≤1/≤1 (97.3%). These results represent the updated nationwide data, which show that the majority of *Candida* BSI isolates was susceptible to all 4 fungal agents tested.

In our previous multicenter study, nearly all isolates (99.7%) had a MIC ≤1 µg/mL for amphotericin B \[[@B5]\]. In the present study, resistance to amphotericin B was found in 5 *Candida* isolates; whereas intermediate resistance was found in 7 isolates. These Vitek-2 results produced no major errors when the E test was used as reference standard, supporting our previous report that Vitek-2 is more sensitive for detecting amphotericin B resistance among *Candida* species than the CLSI method \[[@B4]\].

According to the SENTRY Antimicrobial Surveillance Program \[[@B6]\], the percentages of *Candida* BSI isolates with resistance to fluconazole and voriconazole are 2.5% and 1.2%, respectively. In the present study, resistance to fluconazole was found in 1.4% (9/636) of the *Candida* isolates (4 *C. kruse*i, 3 *C. glabrata*, and 2 *C. parapsilosis*) and resistance to voriconazole was found in 0.9% (6/636) of the *Candida* isolates (1 *C. albicans* and 5 *C. glabrata*), which was comparable with our previous report \[[@B5]\].

Until now, nationwide data on the *in vitro* antifungal activity of flucytosine against *Candida* BSI isolates were not available in Korea. Results from the global SENTRY Antimicrobial Surveillance Program (2008) showed that 95.5% of the 1,201 *Candida* BSI isolates from 5 continents are susceptible to flucytosine \[[@B6]\]. Resistance to flucytosine was noted in 2.4% of *C. albicans*, 0% of *C. glabrata*, 0.5% of *C. parapsilosis*, and 10.3% of *C. tropicalis* isolates \[[@B6]\]. In this study, we showed, for the first time, that 97.3% of *Candida* BSI isolates from Korea were susceptible to flucytosine, as determined by using the Vitek-2 system. Only 3.2% of *C. albicans*, 1.5% of *C. parapsilosis*, 1.4% of *C. glabrata*, and 0% of *C. tropicalis* isolates were resistant to this agent. Again, our results show that the low rates of resistance to flucytosine are consistent with reports from other countries.
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^\*^SDD, I and R (susceptible-dose dependent, intermediate and resistant, respectively), using the Vitek-2 interpretive breakpoint criteria; ^†^Includes *Candida guilliermondii* (10 isolates), *C. famata* (6 isolates), *C. krusei* (4 isolates), *C. pelliculosa* (4 isolates), *C. utilis* (3 isolates), *C. pseudohaemulonii* (2 isolates), *C. lusitaniae* (1 isolate), and *C. intermedia* (1 isolate); ^‡^All 4 *C. krusei* isolates are considered to be resistant to fluconazole, irrespective of the minimum inhibitory concentration (MIC).
